By K.C Balaji
ISBN-10: 3319313398
ISBN-13: 9783319313399
ISBN-10: 331931341X
ISBN-13: 9783319313412
This textual content presents a entire evaluate of pathophysiology, molecular and telephone biology elements of CRPC, discusses all significant scientific trials that experience ended in approval of 6 new medications considering that 2004, explores the position of bone renovation concepts, extensive research of mixture and sequencing thoughts, outlines upcoming novel medications and tendencies in examine, and stresses the function of palliative care during this incurable affliction. dealing with Metastatic Prostate melanoma on your Urological Oncology perform will function a really resource for physicians and researchers facing, and attracted to prostate melanoma. It offers a concise but complete precis of the present prestige of the sector that would aid consultant sufferer administration and stimulate investigative efforts. All chapters are written by way of specialists of their fields and should contain the freshest clinical and scientific information.
Read Online or Download Managing Metastatic Prostate Cancer In Your Urological Oncology Practice PDF
Similar urology books
Read e-book online Botulinum Toxin in Urology PDF
The minimally invasive use of botulinum toxin (BoNT) within the decrease urinary tract has revolutionized the therapy of debilitating bladder, urethra, and prostate stipulations refractory to traditional treatment. this can be the 1st ebook targeting the sensible software of BoNT to the genitourinary tract.
Laparoscopy is a brand new frontier of the surgical method, which lately won an increasing number of reputation and credits upon the surgical groups, additionally in Urology. the explanation remains within the decreased invasivity and within the advances at the concepts of "video-assisted surgery". extra lately the retroperitoneal entry to laparoscopy surgical procedure ("retroperitoneoscopy" or "retroperitoneal laparoscopy") opened a brand new surgical method of a number of diagnostic and operative approaches for quite a few urogenital tract illnesses.
Male genital problems symbolize a typical factor in clinical perform, particularly within the dermatological surroundings. right scientific evaluate of those problems is key while addressing the analysis, which at times may perhaps require histopathological affirmation. looking on the affliction, early prognosis will be not just lifesaving, but additionally of primary significance to the making plans of winning therapy.
This encompassing quantity gathers contributions through popular specialists within the box of pediatric urology to supply a scientific and whole evaluation of the sphere. The ebook opens with a normal part overlaying the root of renal functionality from the fetus to maturity, diagnostic imaging, anesthesia and infections.
- Practical Urological Ultrasound
- Testicular Cancer, An Issue of Urologic Clinics (The Clinics: Surgery)
- Pelvic Floor Dysfunction - A Multidisciplinary Approach
- Cystitis - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
Extra info for Managing Metastatic Prostate Cancer In Your Urological Oncology Practice
Sample text
Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–71. 21. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–38. 22. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al.
Furr BJ. The development of casodex (bicalutamide): Preclinical studies. Eur Urol. 1996;29 (Suppl 2):83–95. 18. Furr BJ, Tucker H. The preclinical development of bicalutamide: Pharmacodynamics and mechanism of action. Urology. 1996;47:13–25. 19. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–90. 20. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Cancer Res. 2011;71:6019–29. can-11-1417. 64. Mistry SJ, Oh WK. New paradigms in microtubule-mediated endocrine signaling in prostate cancer. Mol Cancer Ther. 2013;12:555–66. mct-12-0871. 65. Zhu ML, et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010;70:7992–8002. can-10-0585. 66. Gan L, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 2009;69:8386–94. can-09-1504. 67.
Managing Metastatic Prostate Cancer In Your Urological Oncology Practice by K.C Balaji
by Paul
4.4